Literature DB >> 12934098

Activation of cyclin D1 expression by the ERK5 cascade.

Roseann Mulloy1, Sara Salinas, Alexandre Philips, Robert A Hipskind.   

Abstract

Transcriptional activation of the cyclin D1 gene is a key step in cell proliferation. Accordingly, cyclin D1 overexpression is frequently an early step in neoplastic transformation, particularly in mammary epithelium. Numerous studies have linked elevated cyclin D1 promoter activity to a sustained activation of the ERK1/2 cascade. Here we show that the ERK5 cascade, a distinct mitogen-induced MAPK pathway, can also drive cyclin D1 expression. In CCL39 cells, serum induces a strong, prolonged peak of ERK1/2 and ERK5 phosphorylation, and subsequently elevates cyclin D1 mRNA and protein levels. Overexpression of constitutively active MEK5 and wt ERK5 induces a cyclin D1 reporter gene (D1 -973-luciferase) at least as well as constitutively active MEK1. Activation is blocked by kinase-dead mutants of ERK5 and ERK2, respectively. Mutation of the CRE at -50 in the cyclin D1 promoter decreases activation by the ERK5 but not the ERK1/2 cascade. Importantly, expression of kinase-dead ERK5 diminishes endogenous cyclin D1 protein induction by serum in CCL39 cells and the breast cancer cell lines MCF-7 and HS579. These data identify the cyclin D1 gene as a novel target of the ERK5 cascade, an observation with important implications in cancers involving cyclin D1 deregulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934098     DOI: 10.1038/sj.onc.1206839

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Cyclic fluid shear stress promotes osteoblastic cells proliferation through ERK5 signaling pathway.

Authors:  Peng Li; Yan-chao Ma; Xiao-yun Sheng; Hai-tao Dong; Hua Han; Jing Wang; Ya-yi Xia
Journal:  Mol Cell Biochem       Date:  2012-05       Impact factor: 3.396

2.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 3.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

4.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

Review 5.  Challenges to defining a role for progesterone in breast cancer.

Authors:  Carol A Lange
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

6.  ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Authors:  Jennifer D Cohen; Jaime M C Gard; Raymond B Nagle; Justin D Dietrich; Terrence J Monks; Serrine S Lau
Journal:  Toxicol Sci       Date:  2011-08-02       Impact factor: 4.849

7.  Regulation of ERK5 by insulin and angiotensin-II in vascular smooth muscle cells.

Authors:  Girish Sharma; Marc Lee Goalstone
Journal:  Biochem Biophys Res Commun       Date:  2007-01-26       Impact factor: 3.575

Review 8.  Oncogenic signaling of MEK5-ERK5.

Authors:  Van T Hoang; Thomas J Yan; Jane E Cavanaugh; Patrick T Flaherty; Barbara S Beckman; Matthew E Burow
Journal:  Cancer Lett       Date:  2017-01-30       Impact factor: 8.679

Review 9.  MAPK signalling: ERK5 versus ERK1/2.

Authors:  Satoko Nishimoto; Eisuke Nishida
Journal:  EMBO Rep       Date:  2006-08       Impact factor: 8.807

10.  Role of p90(RSK) in regulating the Crabtree effect: implications for cancer.

Authors:  Emily K Redman; Paul S Brookes; Marcin K Karcz
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.